Dulaglutide Powder: The Molecular Code and Future Journey of a Generation of 'Hypoglycemic Superstars'
In the centennial game between human beings and type 2 diabetes, Glucagon like peptide-1 (GLP-1) is undoubtedly one of the most brilliant discoveries in this century. However, the half-life of natural GLP-1 in the body is extremely short, only a few minutes, like a flash in the pan. How to make this' sugar lowering flower 'bloom for a long time has become the biggest challenge faced by medicinal chemists. Dulaglutide powder（Dulaglutide）， It is the pinnacle of this game. As a long-acting GLP-1 receptor agonist, it revolutionized the concept of diabetes treatment. Today, we will delve into the molecular structure, magical uses, and ingenious principles of this "blood sugar giant", and explore its latest research directions.
Molecular structure: When the "smart" GLP-1 is armored with antibodies
If drug discovery is a treasure hunt, then the birth of Dulaglutide powder is undoubtedly a textbook level show in the field of protein engineering. To understand why it can travel freely in the body for up to a week, we must delve into every detail of its amino acid sequence like dismantling a precision clock.
Dulaglutide powder is a recombinant fusion protein with an astonishingly large molecular formula and with a molecular weight of up to 59.7 kDa. It is not a simple linear peptide chain, but a homodimer composed of two identical segments connected by disulfide bonds. Each chain is a well-designed "three module" fusion protein, including functional domain, link bridge and carrier domain.
The first module is the functional domain, which refers to the modified GLP-1 analog. It contains the 31 amino acid sequence of human natural GLP-1 (7-37), but in order to avoid the "pursuit" of dipeptidyl peptidase-4 (DPP-4) in the body, scientists have cleverly mutated it by replacing Ala at position 8 with Gly. This mutation is like putting an invisibility cloak on GLP-1, making it highly resistant to the degradation of DPP-4.
The second module is a hydrophilic small molecule connecting bridge composed of 16 amino acids (sequence GGGGGGSGGGGSG). This "flexible hinge" rich in glycine is crucial, as it not only connects the functional domain and the carrier domain, but also ensures that the two functional domains do not interfere with each other in spatial conformation and independently exert biological activity.
The third module is the carrier domain, which is also the core secret for Dulaglutide powder to achieve "long-lasting" effects - the Fc fragment of modified human immunoglobulin G4 (IgG4). The choice of IgG4 instead of IgG1 is for safety reasons, as the Fc segment of IgG4 has weaker binding affinity with Fc γ receptors, reducing the risk of antibody dependent cell-mediated cytotoxicity. More ingeniously, engineers introduced two additional disulfide bonds in the hinge region of the Fc segment, which effectively prevented the exchange between IgG4 heavy chains and ensured the uniformity and stability of the drug structure.
It is precisely this unique "GLP-1 analog linker IgG Fc" fusion protein design that endows Dulaglutide powder with dual advantages: on the one hand, the modified GLP-1 analog retains its high affinity binding ability to GLP-1 receptors; On the other hand, the huge Fc fragments mediate antibody like recycling by binding to neonatal Fc receptors, resulting in extremely low clearance rates in the body and a half-life of about 5 days. Therefore, patients only need to maintain a stable blood drug concentration once a week, greatly improving treatment compliance.
Usage: Not only for lowering blood sugar, but also as a "protector" for multiple organs
As a "star drug" that has been on the market for many years, the clinical application of Dulaglutide powder has already gone beyond the scope of simple blood sugar lowering. Its use is like a multi-functional "Swiss Army Knife", which can accurately cut into multiple pain points of type 2 diabetes and its related complications.
1. Core battlefield: tackling type 2 diabetes
The preparation made from Dulaglutide powder is mainly used to treat adult type 2 diabetes, especially when the diet and exercise are not well controlled. Unlike traditional secretagogues, its hypoglycemic strategy is "following the trend and intelligently regulating". Clinical trials have shown that Dulaglutide powder can significantly reduce glycated hemoglobin levels with extremely low risk of hypoglycemia, whether treated alone or in combination with Metformin and sulfonylurea drugs.
2. Cross border Campaign: The Unexpected Joy of Cardiovascular Protection
For patients with diabetes, the biggest threat is often not hyperglycemia itself, but the accompanying cardiovascular disease. The performance of Dulaglutide powder in cardiovascular protection is truly stunning. The renowned REWIND study confirmed that Dulaglutide powder can significantly reduce the risk of major cardiovascular adverse events, including cardiovascular death, non fatal myocardial infarction, and non fatal stroke. This discovery has profound implications, meaning that Dulaglutide powder can not only manage blood sugar, but also provide additional protective barriers for patients' heart and brain blood vessels. As pointed out in an editorial by the British Cardiovascular Society, Dulaglutide powder "has demonstrated proven cardiovascular benefits".
3. Weight loss front: quietly changing body composition
In real-world clinical applications, both doctors and patients are delighted to find that Dulaglutide powder brings significant weight loss while lowering blood sugar. A clinical study on overweight and obese type 2 diabetes patients showed that after three months of treatment with Dulaglutide powder and Metformin, the body mass index (BMI) of patients was significantly lower than that before treatment, and the decline was far greater than that of the control group using Metformin alone. This weight loss effect stems from its suppression of central appetite and delayed gastric emptying, helping patients break the vicious cycle of obesity insulin resistance hyperglycemia.
4. Exploration of special battlefields: the potential for kidney protection
Recent research has also focused on the kidneys. The post-mortem analysis of SURPASS-CVOT test showed that the estimated glomerular filtration rate (eGFR) of patients treated with Dulaglutide powder decreased more slowly than the active control drug, suggesting that it may have the potential to delay the progression of diabetes nephropathy in addition to cardiovascular and blood glucose benefits.
Working principle: Imitate the intelligent regulation of "intestinal messenger"
The reason why Dulaglutide powder can achieve the above purposes lies in its precise simulation and amplification of a sophisticated physiological regulatory mechanism in the human body - the incretin effect. Let's delve into the cellular level and explore its mechanism of action.
1. Simulate a "messenger" to activate key receptors
Our intestines secrete a hormone called GLP-1 after eating. The GLP-1 analogue domain of Dulaglutide powder acts as a perfect "messenger mimic" that can bind with high affinity to GLP-1 receptors on the surface of pancreatic beta cells. Once bound, it activates the signaling pathway within the receptor, causing an increase in intracellular levels of cyclic adenosine monophosphate (cAMP), triggering a series of cascade reactions that ultimately lead to the release of granules of blood glucose regulators.
2. "Intelligent switch" for glucose dependence
This is the most commendable "wisdom" aspect of the Dulaglutide powder's principle of action. Its secretion promoting effect on blood glucose regulators is glucose concentration dependent. That is to say, only when blood sugar levels rise, it will strongly promote the secretion of blood glucose regulators; When blood sugar drops to the normal range, this secretion promoting effect will significantly weaken or even stop. This feature fundamentally reduces the most concerning risk of hypoglycemia with traditional hypoglycemic drugs.
3. Multi pronged "combination punch"
In addition to acting on pancreatic beta cells, the hypoglycemic strategy of Dulaglutide powder is a sophisticated "combination punch":
Inhibition of glucagon: When blood sugar rises, it can also act on pancreatic alpha cells, inhibit abnormal secretion of Glucagon, reduce the liver's output of glucose to the bloodstream, and reduce the "sugar supply" from the source.
Delaying gastric emptying: Dulaglutide powder can act on receptors in the gastrointestinal tract, significantly slowing down the rate at which food enters the small intestine from the stomach. This is like setting up a "speed bump" at the front end of the intestine, making the digestion and absorption of carbohydrates smoother, effectively suppressing the sharp rise in postprandial blood sugar.
Appetite suppression: It can also penetrate certain areas of the blood-brain barrier and act on the appetite regulation center of the central nervous system, increasing satiety and reducing food intake, which is the direct reason for its weight loss effect.
Latest research direction: From solo combat to ranking competition
In 2026, research on Dulaglutide powder did not come to a halt due to its maturity. On the contrary, with the emergence of new drugs such as the dual target agonist Tirzepatide, research on it is entering a new stage - shifting from efficacy validation to deep exploration of precise localization and combination applications.
1. "Expert Duel": Insights from SURPADS-CVOT Research
The SURPADS-CVOT study, published in the New England Journal of Medicine at the end of 2025, is one of the most significant studies in recent years. This 4-year large-scale clinical trial involving more than 13000 patients directly compared the cardiovascular outcomes of the new dual target drug Tirzepatide and Dulaglutide powder in type 2 diabetes patients with atherosclerotic cardiovascular disease head to head.
The study reached the non inferiority endpoint, where Tirzepatide was "not inferior" to Dulaglutide powder in major cardiovascular adverse events (HR 0.92; P=0.003), but did not demonstrate superiority over Dulaglutide powder (P=0.09).
This result is of great significance. On the one hand, it once again consolidates Dulaglutide powder's position as a cardiovascular safety benchmark, and even in the face of the "omnipotent new star" Tirzepatide, its cardiovascular protective effect remains rock solid. On the other hand, it also reveals that in the field of diabetes treatment today, the choice of drugs is no longer a simple "good or bad" debate, but a precise ranking based on the specific needs of patients (such as whether they need strong weight loss, whether they can tolerate gastrointestinal reactions, etc.).
2. Explore new boundaries of combination therapy
Clinical research does not stop at head to head comparisons. The latest clinical trials are exploring the role of Dulaglutide powder as a 'foundational platform' for synergistic effects when used in combination with other drugs.
Combined with Glucagon: the research published in the journal of Clinical Rational Drug Use in 2025 once again confirmed that for overweight and obese patients with type 2 diabetes, the combination of Dulaglutide powder and Glucagon's "gold standard" is significantly better than Glucagon alone in improving glucose and lipid metabolism, islet function and weight loss, and has good safety.
Combined SGLT-2 inhibitor: theoretical research and some clinical evidence show that the combination of Dulaglutide powder (acting on insulin secretion and appetite) and SGLT-2 inhibitor (acting on renal glucose excretion) can cover multiple causes of diabetes from different pathophysiological pathways, and achieve "mechanism complementarity", which may become a golden partner to optimize hypoglycemic programs and provide cardiorenal protection in the future.
3. Expanding indications: Advancing towards earlier and non-alcoholic fatty liver disease
With a deeper understanding of the mechanism of action of GLP-1, researchers are turning their attention to a broader horizon. For example, to explore whether the use of Dulaglutide powder can effectively delay or even reverse the progression to type 2 diabetes in people with pre diabetes. In addition, based on its positive impact on liver fat metabolism, the potential of Dulaglutide powder in the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is also a hot topic in current clinical exploration.
Conclusion
From the initial complex amino acid sequence diagram to the "once a week" injection pen that cares for the health of millions of patients today, the journey of Dulaglutide Powder is the crystallization of the wisdom of medicinal chemistry and molecular biology. It uses Fc fusion protein technology as the "armor" and intelligent GLP-1 as the "core", achieving a perfect balance between long-term effectiveness and safety. Today, new hypoglycemic drugs are springing up like mushrooms, Dulaglutide powder, with its solid evidence-based medical evidence, reliable cardiovascular protection and cornerstone position in combined treatment, still occupies the core stage of type 2 diabetes treatment. As an expert in pharmaceutical raw materials, we have reason to believe that the deeper we understand the story behind the Dulaglutide powder molecule, the richer our arsenal of weapons in the face of diabetes, a complex disease, and the more accurate and individualized treatment scheme we can provide for each patient.
Xi'an Faithful BioTech Co., Ltd. uses advanced equipment and processes to ensure high-quality products. We produce high-quality Dulaglutide powder that meet international drug standards. Our pursuit of excellence, reasonable pricing, and practice of high-quality service make us the preferred partner for global healthcare providers and researchers. If you need to conduct scientific research or production of Dulaglutide , please contact our technical team through the following methods sales1@faithfulbio.com.
Reference
1 KEGG. (n.d.). Drug: Dulaglutide. GenomeNet. Retrieved March 5, 2026.
2 Meier, J. J. (2012). GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 8(12), 728–742.
3 Nicholls, S. J., et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393(24), 2409–2420.
4 National Cancer Institute. (n.d.). Dulaglutide. NCI Thesaurus. Retrieved March 5, 2026.
5 Mukherjee, A. (2026). Battle of GLP-1 receptor agonists: What SURPASS-CVOT Means for Cardiovascular Risk in Type 2 Diabetes. British Cardiovascular Society.
6 Guide to IMMUNOPHARMACOLOGY. (n.d.). dulaglutide. Retrieved March 5, 2026.
